The table below shows Denali Therapeutics Inc.'s income statement line items across its last 6 fiscal years, exactly as reported in the company's audited annual filings. All figures are in US dollars; negative values appear in red.
Line item
FY 2025
FY 2024
FY 2023
FY 2022
FY 2021
FY 2020
Revenue
$0.00
$0.00
$330.53M
$108.46M
$48.66M
$335.66M
Cost of revenue
-
-
-
-
-
-
Gross profit
-
-
-
-
-
-
R&D
$418.78M
$396.44M
$423.88M
$358.73M
$265.35M
$212.62M
SG&A
DNLI annual revenue (10-K history)
Denali Therapeutics Inc. reported annual revenue of $0.00 for fiscal year 2025. Figures come from the company's audited annual reports as filed with the SEC.